Powder: -20°C for 3 years | In solvent: -80°C for 1 year
APNEA ((2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol) is a non-selective agonist of adenosine A3 receptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 30.00 | |
10 mg | In stock | $ 42.00 | |
25 mg | In stock | $ 65.00 | |
50 mg | In stock | Inquiry | |
1 mL * 10 mM (in DMSO) | In stock | $ 41.00 |
Description | APNEA ((2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol) is a non-selective agonist of adenosine A3 receptor. |
In vitro | APNEA at the subprotective dose of 1 mg/kg against electroconvulsions, significantly potentiated the anticonvulsive action of phenobarbital, diphenylhydantoin and valproate against maximal electroshock, being ineffective at lower doses[2]. |
In vivo | APNEA (0.0039-1 mg/kg) enhanced the protective activity of carbamazepine. APNEA (0.0156 and 1 mg/kg) administered alone or in combination with carbamazepine significantly decreased the body temperature and impaired long-term memory[2]. |
Synonyms | (2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol, N6-[2-(4-Aminophenyl)ethyl]adenosine |
Molecular Weight | 386.41 |
Formula | C18H22N6O4 |
CAS No. | 89705-21-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 200 mg/mL (517.58 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
APNEA 89705-21-5 GPCR/G Protein Neuroscience Adenosine Receptor (2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol N6-[2-(4-Aminophenyl)ethyl]adenosine inhibitor inhibit